|
An Industry Panel and Networking Reception
Thursday, June 3, 2010
Agenda
3:00 PM - 3:30 PM Registration and Networking
3:30 PM - 5:00 PM Industry Panel
5:00 PM - 6:30 PM Networking Reception
Effectively raising capital is crucial for any company. Although VC's are a traditional source of funds, there are many opportunities for financing that can get your company to where you need it to be. You just need to know the right people.
Join our panel to hear from private wealthy individuals, government granting agencies, foundations, angels and VCs who have opportunities for you to fund your company.
Our Panel discussions are candid, interactive and informal. We want you to walk away with the real story behind how things work so you can make it happen yourself. This Panel will be followed by a Networking Reception.
Speakers
• Jon Mogford, Ph.D., Acting Deputy Director Defense Sciences Office , DOD
• Elaine Heron, Chair and Chief Executive Officer, Amplyx Pharmaceuticals, Inc.and Member, Life Science Angels, Inc.
• David Beylin, Program Manager, SBIR Development Center, National Cancer Institute
• Guy Miller MD, PhD, Chairman & CEO, Edison Pharmaceuticals
• Lead Facilitator: Gregory W. Heibel, Partner, Corporate Group, Emerging Companies Group Member, Orrick, Herrington & Sutcliffe LLP
• Foundation perspective TBC. Invited speakers include: Regina Rabinovich, Director, Infectious Diseases, The Bill & Melinda Gates Foundation | Deborah Walsh, Executive Director, Lung Cancer Research Foundation | PJ Handeland, President, Arthritis Foundation
Cost & Registration
• Regular Price: $60
• Partners' Network: $50
• BioCenter Members: Free (please RSVP to Aurélie)
• On-site Registration: add $10 to the above
This event is typically sold out, so early pre-registration is recommended to avoid disappointment on the day!
Venue
Orrick, Herrington & Sutcliffe LLP
1000 Marsh Road
Building 1100
Menlo Park, CA 94025-1015
Click here for Venue Directions»
Speakers Bios
Jon Mogford, Ph.D., Acting Deputy Director Defense Sciences Office , DARPA
Dr. Jon Mogford is the Acting Deputy Director in the Defense Sciences Office with interests in wound healing/regeneration, cellular therapies, tissue engineering, and vascular physiology. Dr. Mogford received his doctorate in medical sciences (physiology) from the Texas A&M Health Science Center and performed post-doctoral work at the University of Chicago. He later served as a Research Assistant Professor at Northwestern University. His research background includes studies on the role of growth factors, age, and ischemia/hypoxia on dermal wound healing/scarring and on the control of cell phenotype and microvascular function by cell adhesion receptors, growth factors, and extracellular matrix
Elaine Heron, Chair and Chief Executive Officer, Amplyx Pharmaceuticals, Inc.and Member, Life Science Angels, Inc.
Since February 2009, Dr. Elaine Heron has been Chair and Chief Executive Officer of Amplyx Pharmaceuticals, Inc., an early stage drug development company. Her operational involvement in the company followed an angel investment in Amplyx through Life Science Angels. From July 2001 to October 2009, she was Chairman and Chief Executive Officer of Labcyte Inc., a product stage life science research tools company where she led raising of $43M in venture capital. She remains on the board of directors of Labcyte. Before joining Labcyte, she spent six years in increasing responsible positions at the Applied Biosystems Group of Applera Corporation, including General Manager and Vice President, Marketing and Sales. Dr.. Heron earned a B.S. in Chemistry with highest distinction and a Ph.D. in analytical biochemistry from Purdue University and also holds an M.B.A.
Dr. Heron is also a member of the board of directors of Fluxion Biosciences, a product stage life science tools company, which was funded by Life Science Angels, and of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) where she chairs the Corporate Governance and Nomination Committee and serves on the audit committee. She is an active member of Life Science Angels and a member of its bio screening committee.
David Beylin, Program Manager, SBIR Development Center, National Cancer Institute
David Beylin is a Program Manager with the SBIR Development Center at the National Cancer Institute, where he assists small businesses in the medical imaging field in securing government funding for innovative research and development projects with high commercial potential. David has over 10 years of experience in research, development and commercialization of scientific and medical instrumentation and molecular imaging agents. Previously, David was involved with X/Seed Capital Management, LLC, a seed-stage venture capital firm investing in breakthrough technologies. Prior to X/Seed, David worked for Naviscan PET Systems, Inc. in a variety of technical and management roles, including Vice President of Research, concentrating on the design, clinical validation, and regulatory clearance of high resolution Positron Emission Tomography devices and image-guided interventions. Mr. Beylin was trained in experimental nuclear physics at the Budker Institute of Nuclear Physics (Russia) and the KEK-High Energy Accelerator Research Organization (Japan). Mr. Beylin is certified in Nuclear Medicine Physics and Instrumentation by the American Board of Science in Nuclear Medicine.
Guy Miller MD, PhD, Chairman & CEO, Edison Pharmaceuticals
Guy Miller, MD, PhD, is the Chairman and Chief Executive Officer of Edison Pharmaceuticals. He holds a clinical faculty appointment at Stanford University School of Medicine/PAVAMC, in medical-surgical critical care and is an Adjunct Professor, University of North Carolina, School of Public Health. Prior to Edison, he founded Galileo Pharmaceuticals, and was its Chairman and CEO from 1995-2005. Dr. Miller completed a surgical internship at the University of Chicago and residency and fellowship in anesthesiology & critical care medicine at Johns Hopkins, where he was an Assistant Professor until 1995.
Edison has obtained substantial non-dilutive peer-reviewed grant support to advance both its pre-clinical and clinical initiatives from foundations including the Muscular Dystrophy Association, Friedreich's Ataxia Research Alliance, and Seek A Miracle. The company closed Series A Preferred Stock Offering in November 2005, and Series B Financing led by Mr. Carl Berg, Berg & Berg Enterprises, LLC. New investors included John W. Marriott, III, President and CEO of JWM, LP, and JWM Family Enterprises.
Lead Facilitator: Gregory W. Heibel, Partner, Corporate Group, Emerging Companies Group Member, Orrick, Herrington & Sutcliffe LLP
Greg Heibel, a partner in the Silicon Valley office, is a member of the Emerging Companies Group, which advises emerging and public technology companies, venture capital firms and other technology investors, as well as Orrick's Energy Group.
Mr. Heibel’s practice includes the formation, financing and general corporate counseling of rapidly growing technology companies; the representation of venture capital firms and other investors in private and public offerings, as well as other complex transactions related to high growth companies.
Mr. Heibel has completed hundreds of financings, mergers, acquisitions and intellectual property transactions for clients in the networking, wireless, Internet, software, life sciences and consumer industries. Additionally, Mr. Heibel has represented numerous Nasdaq listed companies in their public offering, mergers and acquisitions and ongoing corporate governance needs, including Foundry Networks, Virage Networks, Adeza, Laserscope, Intellisync and Preview Systems.
|
